» Articles » PMID: 29399543

The Effect of Mesenchymal Stem Cell-Derived Extracellular Vesicles on Hematopoietic Stem Cells Fate

Overview
Journal Adv Pharm Bull
Date 2018 Feb 6
PMID 29399543
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Hematopoietic stem cells (HSCs) are multipotent stem cells, with self-renewal ability as well as ability to generate all blood cells. Mesenchymal stem cells (MSCs) are multipotent stem cells, with self-renewal ability, and capable of differentiating into a variety of cell types. MSCs have supporting effects on hematopoiesis; through direct intercellular communications as well as secreting cytokines, chemokines, and extracellular vesicles (EVs). Recent investigations demonstrated that some biological functions and effects of MSCs are mediated by their EVs. MSC-EVs are the cell membrane and endosomal membrane compartments, which are important mediators in the intercellular communications. MSC-EVs contain some of the molecules such as proteins, mRNA, siRNA, and miRNA from their parental cells. MSC-EVs are able to inhibit tumor, repair damaged tissue, and modulate immune system responses. MSC-EVs compared to their parental cells, may have the specific safety advantages such as the lower potential to trigger immune system responses and limited side effects. Recently some studies demonstrated the effect of MSC-EVs on the expansion, differentiation, and clinical applications of HSCs such as improvement of hematopoietic stem cell transplantation (HSCT) and inhibition of graft versus host disease (GVHD). HSCT may be the only therapeutic choice for patients who suffer from malignant and non-malignant hematological disorders. However, there are several severe side effects such GVHD that restricts the successfulness of HSCT. In this review, we will discuss the most important effects of MSCs and MSC-EVs on the improvement of HSCT, inhibition and treatment of GVHD, as well as, on the expansion of HSCs.

Citing Articles

Isolation, identification, and challenges of extracellular vesicles: emerging players in clinical applications.

Ma X, Peng L, Zhu X, Chu T, Yang C, Zhou B Apoptosis. 2024; 30(1-2):422-445.

PMID: 39522104 DOI: 10.1007/s10495-024-02036-2.


Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia.

Wu C, Weng T, Li J, Wu K Int J Mol Sci. 2024; 25(5).

PMID: 38473775 PMC: 10932140. DOI: 10.3390/ijms25052527.


Mesenchymal stromal cell-derived secretome-based therapy for neurodegenerative diseases: overview of clinical trials.

Ghasemi M, Roshandel E, Mohammadian M, Farhadihosseinabadi B, Akbarzadehlaleh P, Shamsasenjan K Stem Cell Res Ther. 2023; 14(1):122.

PMID: 37143147 PMC: 10161443. DOI: 10.1186/s13287-023-03264-0.


Bone marrow-derived extracellular vesicles carry the TGF-β signal transducer Smad2 to preserve hematopoietic stem cells in mice.

Gautheron F, Georgievski A, Garrido C, Quere R Cell Death Discov. 2023; 9(1):117.

PMID: 37019878 PMC: 10076352. DOI: 10.1038/s41420-023-01414-0.


Engineered Tissue Models to Replicate Dynamic Interactions within the Hematopoietic Stem Cell Niche.

Gilchrist A, Harley B Adv Healthc Mater. 2021; 11(7):e2102130.

PMID: 34936239 PMC: 8986554. DOI: 10.1002/adhm.202102130.


References
1.
Pelagiadis I, Stiakaki E, Choulaki C, Kalmanti M, Dimitriou H . The role of children's bone marrow mesenchymal stromal cells in the ex vivo expansion of autologous and allogeneic hematopoietic stem cells. Cell Biol Int. 2015; 39(10):1099-110. DOI: 10.1002/cbin.10483. View

2.
Sanchez-Guijo F, Caballero-Velazquez T, Lopez-Villar O, Redondo A, Parody R, Martinez C . Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014; 20(10):1580-5. DOI: 10.1016/j.bbmt.2014.06.015. View

3.
Chen J, Li C, Chen L . The Role of Microvesicles Derived from Mesenchymal Stem Cells in Lung Diseases. Biomed Res Int. 2015; 2015:985814. PMC: 4443645. DOI: 10.1155/2015/985814. View

4.
Fan X, Gay F, Ong S, Ang J, Chu P, Bari S . Mesenchymal stromal cell supported umbilical cord blood ex vivo expansion enhances regulatory T cells and reduces graft versus host disease. Cytotherapy. 2013; 15(5):610-9. DOI: 10.1016/j.jcyt.2012.12.007. View

5.
Gatti S, Bruno S, Deregibus M, Sordi A, Cantaluppi V, Tetta C . Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant. 2011; 26(5):1474-83. DOI: 10.1093/ndt/gfr015. View